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A systematic review of comparative studies
of tiotropium Respimat® and tiotropium
HandiHaler® in patients with chronic
obstructive pulmonary disease: does
inhaler choice matter?
Ronald Dahl1* and Alan Kaplan2
Abstract
Background: In many countries worldwide, the long-acting anticholinergic drug tiotropium is available as a dry
powder formulation delivered by means of the HandiHaler® inhalation device and as an aqueous solution delivered
via the Respimat® Soft Mist™ Inhaler. Tiotropium HandiHaler® is a single-dose, dry powder, breath-actuated inhaler
that provides delivered doses and lung deposition of tiotropium that are, over a wide range, not influenced by the
severity of chronic obstructive pulmonary disease (COPD). Tiotropium Respimat® is a propellant-free, multi-dose
inhaler that delivers a metered dose of medication as a fine, slow-moving, long-lasting soft mist, independently of
patient inspiratory effort. The high fine-particle fraction of droplets produced by the Respimat® inhaler optimizes
the efficiency of drug delivery to the lungs.
Methods: To help inform the choice of tiotropium inhaler for prescribers and patients, this systematic review
summarizes the available pharmacokinetic, efficacy and safety data from comparative studies of tiotropium
Respimat® and tiotropium HandiHaler® in COPD, focusing on the licensed once-daily doses of 5 and 18 μg,
respectively. Data sources reviewed include publications and abstracts identified from database searches.
Results: Published evidence from comparative studies suggests that tiotropium Respimat® 5 μg and tiotropium
HandiHaler® 18 μg provide similar clinical outcomes in patients with COPD.
Conclusions: The findings indicate that physicians can base their decision about an inhaler for tiotropium on
factors other than efficacy or safety. These could be patient preference for a particular inhaler, ease of use and the
efficiency of drug delivery, with the aim of optimizing adherence and clinical outcomes with long-term tiotropium
maintenance therapy.
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Inhaler
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Background
Current guidelines for the management of chronic
obstructive pulmonary disease (COPD) recommend
maintenance treatment with inhaled bronchodilator
therapy and a variety of inhaler devices are currently
available, with different technical properties, levels of
drug deposition within the lungs and modes of oper-
ation. The choice of inhalation device is important
because it can influence patients’ adherence to ther-
apy, which can potentially affect long-term outcomes
in a chronic disease such as COPD [1].
The long-acting anticholinergic drug tiotropium is
available in many countries as a dry powder formula-
tion delivered by means of the HandiHaler® inhaler
device (Boehringer Ingelheim International GmbH,
Ingelheim, Germany) [2, 3] and as an aqueous solution
delivered via the Respimat® Soft Mist™ Inhaler (Boehringer
Ingelheim International GmbH) [4, 5]. The efficacy and
safety profile of tiotropium HandiHaler® in patients with
COPD is well established, based on numerous clinical
studies and also extensive post-marketing experience
since its approval in Europe in 2002 and in the
United States in 2004 [2–5]. Tiotropium Respimat®
was approved as a COPD maintenance bronchodilator
in 2007 in Europe and in 2014 in the United States
and Canada [4–8].
Tiotropium HandiHaler® is a single-dose, dry pow-
der, breath-actuated inhaler that provides consistent
rates of delivered doses and lung deposition of tiotro-
pium that are, over a wide range, not influenced by
the severity of COPD [9]. In-vitro data have shown
that the delivered dose of tiotropium was consistent
at flow rates ranging from 20 to 60 L/min [10], and
fine particle dose and fine particle fraction (defined as
the mass fraction of particles with an aerodynamic
diameter <5.8 μm) [11] were consistent at flow rates
between 28.3 and 60 L/min, with a decline in fine
particle dose of approximately 20% observed when
flow rates decreased from 28.3 to 20 L/min [10]. In-vivo
study data confirmed that COPD patients across a
wide range of severities were able to generate suffi-
cient inspiratory flow rates to activate the tiotropium
HandiHaler® [10]. These findings indicate that the
large majority of patients, irrespective of stage of
COPD, can achieve acceptable delivery of medication
through the tiotropium HandiHaler®.
Tiotropium Respimat® is a propellant-free multi-
dose inhaler that uses mechanical power from a
spring to deliver a metered dose of medication as a
fine, slow-moving, long-lasting soft mist [11]. The
inhaler was developed as an active system with a
constant energy source, and the quality of dose and
particle size distribution is uniquely independent of
the patient’s inspiratory flow rate [12–15]. The
tiotropium Respimat® inhaler aerosolizes the majority
of each metered dose in the form of droplets of
>1 μm (to avoid loss of small droplets during subse-
quent exhalation) and <5.8 μm (to facilitate efficient
lung deposition through the mechanism of sedimen-
tation); particles that are too large (≥6 μm) deposit in
the oropharynx and large conducting airways,
therefore having no clinical effect [11, 16, 17]. The
fine particle fraction (defined as the proportion of
drug mass in aerosolized particles that is carried by
particles with an aerodynamic diameter of not more
than 5.8 μm) is 65–80% [15, 18]. This high fine
particle fraction, combined with the low velocity and
long duration of the aerosol, results in a high level of
drug deposition in the lungs and reduced oropharyngeal
deposition [12, 14, 19]. This allows a more than 3-fold
lower nominal dose of tiotropium to be administered
compared with tiotropium HandiHaler® [7, 12, 20]; a
quantitatively higher fraction of the inhaled dose is
delivered to the bronchial system, with qualitatively
higher distribution throughout the lung compared
with other devices [21].
Both the tiotropium HandiHaler® and tiotropium
Respimat® inhalers are available in many countries
worldwide for the delivery of tiotropium as a main-
tenance treatment for COPD. Consequently, a de-
tailed evaluation of their respective effects on clinical
outcomes is warranted to help inform the choice of
inhaler for prescribers and patients [7, 22]. The
objective of this review was to summarize and evalu-
ate the available pharmacokinetic, efficacy and safety
data that have been published and presented to date
from comparative studies of tiotropium Respimat®
and tiotropium HandiHaler® in patients with COPD,
focusing on the once-daily licensed doses of 5 and
18 μg, respectively.
Methods
A systematic literature search was conducted for all
interventional and non-interventional study publications
containing the terms “tiotropium” AND “Respimat”
AND “HandiHaler” AND “COPD”, using the following
online sources: US National Library of Medicine,
National Institutes of Health PubMed database;
American Thoracic Society (ATS) and European
Respiratory Society (ERS) congress abstracts; British
Thoracic Society (BTS) congress abstracts (via the
Thorax journal website) as well as the Chest journal
website. Limits were not placed upon the language of
the publication. The period searched was 2006–30
September 2015 for congress proceedings and any
time up to 30 September 2015 for PubMed and the
Thorax and Chest journal websites. Clinical trials
were also searched, using the terms “tiotropium”
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AND “Respimat” AND “HandiHaler” AND “COPD” at
www.clinicaltrials.gov.
The total hits from the search were assessed for
their relevance (based on titles/abstracts), and those
publications that were deemed potentially relevant
(i.e. including comparative data for tiotropium Respi-
mat® and tiotropium HandiHaler® in patients with
COPD) were obtained in full for analysis. The re-
searcher then examined the Methods and Results sec-
tions of the publications to extract and summarize
the data for tiotropium Respimat® 5 μg and tiotro-
pium HandiHaler® 18 μg.
Duplicate publications, republished papers, studies
not comparing tiotropium Respimat® and tiotropium
HandiHaler® efficacy, safety or pharmacokinetic data
(at the licensed doses), studies in non-COPD pa-
tients and secondary/review publications that did not
report original data were excluded from the analysis.
The trial list from www.clinicaltrials.gov was com-
pared against the literature search results to exclude
trials with data already covered by the publications.
Results
Summary of search results
A total of 89 hits resulted from database searches (ATS
abstracts = 10; ERS abstracts = 18; Thorax journal = 18 [in-
cluding seven BTS abstracts and 11 other publications];
Chest journal = 13 [including nine meeting abstracts and
four other publications]; PubMed = 30 publications). The
number of records identified, included and excluded, and
the reasons for exclusions are summarized in Fig. 1.
The total number of manuscript publications from this
search that contained tiotropium Respimat® and tiotro-
pium HandiHaler® data was 45. Of the 45 records, 35
publications were excluded for the following reasons:
one reported trial design/rationale only (no results); one
was a duplicate publication (included in both Thorax
and PubMed search results); one was a republished
paper (both publications were listed in the PubMed
search results); seven studies did not include compara-
tive efficacy, safety or pharmacokinetic data on tiotro-
pium Respimat® and tiotropium HandiHaler® at the
licensed doses; one study was not conducted in COPD
patients; 24 publications did not include original data/
analyses (13 review/commentary/opinion articles, eight
correspondence articles, one editorial, one health care
institute report; one treatment guidelines document). An
additional manuscript submitted for publication was in-
cluded in the analysis, as the authors considered it to be
relevant (providing further evidence to address key ques-
tions posed in this review).
The number of congress presentation (ATS, ERS, BTS,
Chest) abstracts from this search that contained tiotro-
pium Respimat® and tiotropium HandiHaler® data was
44. Of the 44 records, 33 abstracts were excluded for the
following reasons: 19 did not include comparative
Fig. 1 Flow diagram to show number of records identified, together with the numbers of records included and excluded, with reasons for exclusion
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efficacy or safety data on tiotropium Respimat® and tio-
tropium HandiHaler® at the licensed doses; four studies
were not in COPD; nine studies with data also published
in full papers (full publications were listed in search re-
sults); and 1 was a duplicate abstract (presented at both
BTS and ATS). Therefore, 22 publications in total were
included in this review (11 manuscripts and 11 congress
presentation abstracts) (for a complete list, see Add-
itional file 1: Table S1) [23–44]. The characteristics of
the clinical trials assessing tiotropium Respimat® and tio-
tropium HandiHaler® at the licensed doses (and reported
as primary publications) and the pooled, combined and
database studies covered by this review are summarized
in Table 1.
The search of www.clinicaltrials.gov provided 13
records and all 13 were excluded from the systematic
review for the following reasons: seven trials were
completed with data published in manuscripts or
abstracts already selected for the current analysis; six
trials did not include comparative data on tiotropium
Respimat® and tiotropium HandiHaler® at the licensed
doses (five trials compared tiotropium Respimat® or
tiotropium HandiHaler® with other therapies [olodaterol
or indacaterol]; one observational study showed only
combined results for tiotropium Respimat® together
with tiotropium HandiHaler®).
Pharmacokinetic properties of tiotropium Respimat® and
tiotropium HandiHaler®
In several clinical trials, tiotropium Respimat® 5 μg
and tiotropium HandiHaler® 18 μg have demonstrated
similar pharmacokinetic profiles [26, 31, 33, 37].
Urinary excretion (pre- and post-dose measures) of
tiotropium Respimat® 5 μg was comparable with that
of tiotropium HandiHaler® 18 μg [26] and plasma
profiles were similar for tiotropium Respimat® 5 μg
and tiotropium HandiHaler® 18 μg [33, 37].
Previously, it had been suggested that systemic
exposure with tiotropium Respimat® might be greater
than with tiotropium HandiHaler®, with associated
potential for increased risk of toxicity [45, 46].
However, a recent extensive study comparing the
pharmacokinetic properties of tiotropium adminis-
tered via the two inhalers showed that systemic
exposure to tiotropium (as shown by mean plasma
concentration profile at steady state) was lower in
patients with COPD treated with tiotropium Respimat®
5 μg compared with patients treated with tiotropium
HandiHaler® 18 μg [31]. The crossover design study
included five 4-week treatment periods of placebo
and once-daily doses of tiotropium Respimat® 1.25,
2.5 and 5 μg, and tiotropium HandiHaler® 18 μg.
Based on the findings of earlier studies in COPD
patients, which showed that pharmacokinetic steady
state was achieved after 2–3 weeks of once-daily
dosing with tiotropium, with no further accumulation
after this time [37, 47], 4 weeks was considered to be
sufficient to reach pharmacokinetic and pharmacody-
namic steady state. Figure 2 shows mean plasma
concentrations of tiotropium from 2 min to 6 h post-
dosing with tiotropium HandiHaler® 18 μg and tiotropium
Respimat® 5 μg.
Efficacy of tiotropium Respimat® compared with
tiotropium HandiHaler®
Lung function parameters
The efficacy of tiotropium Respimat® compared with
tiotropium HandiHaler® has been compared in
several short-term, randomized, double-blind, multi-
centre Respimat® dose-finding trials in patients with
COPD [26, 31, 33, 37]. These studies showed that
mean trough forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) values after 3–4
weeks of treatment were most comparable for once-
daily tiotropium Respimat® 5 μg and tiotropium
HandiHaler® 18 μg (vs. alternative tiotropium Respimat®
doses of 1.25, 2.5 or 10 μg).
Quality of life
Data from 16 clinical trials (13 tiotropium HandiHaler®,
three tiotropium Respimat®) were analysed to assess the
effects of tiotropium, delivered via HandiHaler® or
Respimat®, on health-related quality of life (HRQoL)
in patients with moderate to very severe COPD
(tiotropium HandiHaler® 18 μg, n = 5646; active com-
parator, two trials, n = 584; placebo comparator, 11
trials, n = 4853; tiotropium Respimat® 5 μg, three
trials, n = 2219; tiotropium Respimat® 10 μg, two
trials, n = 619; placebo comparator, three trials, n = 2318)
[34]. HRQoL was evaluated using the St George’s
Respiratory Questionnaire (SGRQ) total score. Although
treatment effects varied slightly between trials, per-
haps due to differences in study design, similar im-
provements in HRQoL were seen with tiotropium
overall, irrespective of whether it was delivered by
HandiHaler® or Respimat®. The mean change in SGRQ
for tiotropium HandiHaler® compared with placebo
ranged from –1.37 to –6.52 (statistically significant
difference in 9 of 11 trials, p <0.05), and for tiotropium
Respimat® 5 μg compared with placebo it ranged from
–2.94 to –3.71 (statistically significant difference in all
three trials, p <0.01) (Fig. 3) [34].
Sleep quality study
Patients with COPD can be affected by disordered gas
exchange and poor sleep quality. A study was performed to
compare the effect of tiotropium Respimat® and tiotropium
HandiHaler® on sleeping arterial oxygen saturation (SaO2)
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Table 1 Primary tiotropium trials and pooled, combined and database analyses included in this review. Publications were limited to those reporting tiotropium Respimat® and
tiotropium HandiHaler® data at the licensed doses
NCT identifier and
citation(s)
Study design COPD inclusion criteria Baseline lung
function values
Patient numbers and
treatment groups
Endpoints
Primary tiotropium trial publications
NCT02175342
Caillaud D, et al. Int J
Chron Obstruct Pulmon
Dis. 2007;2:559–65 [26]
Multicentre, randomized, double-blind within
device (no blinding between RMT and HH),
parallel-group, 3-week dose-ranging Phase
II study
FEV1/FVC ≤70%
FEV1 30–65% predicted
Smoking history ≥10 pack-
years
Mean FEV1 44%
predicted
n = 202
RMT 5 μg
(n = 25)
HH 18 μg
(n = 25)
Efficacy 1o: mean
change in trough FEV1
from baseline to Day 21
2o: FVC and rescue
medication use
NCT01222533
Hohlfeld JM, et al.
J Clin Pharmacol.
2014;54:405–14 [31]
Comparative, multicentre, placebo-controlled,
randomized (double-blind within RMT 1.25, 2.5,
5 μg; open-label HH 18 μg), 5-way crossover
trial with 4-week treatment periods
FEV1/FVC <70%
FEV1 < 80% predicted
FEV1/FVC 45%
Mean FEV1 54%
predicted
n = 154
RMT 5 μg
(n = 150)
HH 18 μg
(n = 146)
Efficacy 1o: trough FEV1
at end of 24-h dosing
interval
2o: FVC, peak expiratory
flow and rescue
medication use
NCT00292448
Ichinose M, et al.
Respir Med.
2010;104:228–36 [33]
Randomized, double-blind, double-dummy,
2-way, 4-week crossover, Phase II study of
Japanese patients with COPD
FEV1/FVC ≤70%
FEV1≤ 70% predicted
Current or ex-smokers
FEV1/FVC 42%
Mean FEV1 43%
predicted
n = 157
RMT 5 μg
(n = 147)
HH 18 μg
(n = 147)
Efficacy 1o: trough FEV1
response
2o: peak and average
FEV1 and FVC
NCT00239447 and
NCT00281567
van Noord JA, et al.
Respir Med.
2009;103:22–9 [37]
Pre-specified, pooled analysis of two identical,
30-week, double-blind, double-dummy, crossover
studies (4-week crossover periods)
FEV1/FVC ≤70%
FEV1≤ 60% predicted
Mean FEV1 37%
predicted
n = 207
Included in efficacy and
safety analyses:
RMT 5 μg (n = 189)
HH 18 μg (n = 189)
Efficacy 1o: trough FEV1
from baseline to Day 29
2o: trough and peak
FVC, FVC AUC(0-12h),
peak FEV1 and FEV1
AUC(0-12h) at
Day 29, and the time to
therapeutic response
TIOSPIR® 205.452/
NCT01126437
Wise RA, et al.
N Engl J Med.
2013;369:1491–501 [48]
Randomized, double-blind, double-dummy,
parallel-group, event-driven trial, duration
2–3 years
FEV1/FVC ≤70%
FEV1≤ 70% predicted
Mean post-
bronchodilator FEV1
48% predicted for
total population
n = 17,135
At risk, mortality
RMT 5 μg (n = 5711)
RMT 2.5 μg (n = 5730)
HH 18 μg (n = 5694)
At risk, exacerbation
RMT 5 μg (n = 5705)
RMT 2.5 μg (n = 5724)
HH 18 μg (n = 5687)
Safety 1o: time to all-
cause mortality
Efficacy 1o: time to first
COPD exacerbation
Secondary outcomes:
number of
exacerbations; time to
the first MACE
TIOSPIR® 205.452/
NCT01126437
Anzueto A, et al.
Respir Res. 2015;16:107 [24]
Spirometry sub-study
Randomized, double-blind, double-dummy,
parallel-group, event-driven trial, duration
2–3 years
FEV1/FVC ≤70%
FEV1≤ 70% predicted
Mean post-
bronchodilator FEV1
48% predicted for
total population
n = 1370
RMT 5 μg (n = 461)
HH 18 μg (n = 445)
Trough FEV1 and FVC
Bouloukaki I, et al.
Sleep Breath. 2015 [25, 44]
Randomized parallel-group trial Mild to moderate COPD
(resting arterial oxygen
tension >60 mmHg while
awake)
NR n = 200 randomized
RMT (n =100)
HH (n =100
Patients analysed:
RMT (n = 95)
HH (n = 93)
SaO2 and sleep quality
D
ahland
Kaplan
BM
C
Pulm
onary
M
edicine
 (2016) 16:135 
Page
5
of
17
Table 1 Primary tiotropium trials and pooled, combined and database analyses included in this review. Publications were limited to those reporting tiotropium Respimat® and
tiotropium HandiHaler® data at the licensed doses (Continued)
Pooled, combined and database analyses
Tashkin D, et al. Chest.
2014;146 r_Meeting
Abstracts:49A [34]
16 clinical trials (13 tiotropium HandiHaler®, 3 tiotropium
Respimat®)
Moderate to very severe
COPD
NR HH 18 μg (13 trials,
n = 5646)
Active comparator
(2 trials, n = 584)
Placebo (11 trials,
n = 4853)
RMT 5 μg (3 trials,
n = 2219)
RMT 10 μg (2 trials,
n = 619)
Placebo (3 trials,
n = 2318)
HRQoL evaluated using
the SGRQ
Dahl R, et al.
Eur Respir J. 2014;44
Suppl 58:925 [28]
Post-hoc, pooled analysis of all placebo-controlled or
head-to-head trials of RMT 5 μg and HH 18 μg with vital
status follow up (analysed for death) and those with
duration of at least 1 year (analysed for exacerbations)
COPD NR At risk of mortality,
6 trials:
RMT 5 μg (n = 8760)
HH 18 μg (n = 8680)
Placebo (n = 6053)
At risk of exacerbations,
5 trials:
RMT 5 μg (n = 8314)
HH 18 μg (n = 8673)
Placebo (n = 5612)
Number of deaths
Number of patients with
≥1 exacerbation
Halpin DMG, et al.
Int J Chron Obstruct
Pulmon Dis. 2015;10:239–
59 [30]
Pooled analysis of adverse event data from 28 HH and 7
RMT studies
FEV1≤ 70% of FVC Mean FEV1 41%
predicted
Patients treated:
RMT 5 μg (n = 3282)
RMT placebo (n = 3283)
HH 18 μg (n = 9647)
HH placebo (n = 8343)
Safety: AEs
Hohlfeld JM, et al.
Int J Clin Pract.
2015;69:72–80 [32]
Combined analysis of all tiotropium trials in COPD involving
Holter ECG monitoring and conducted between 2003 and
2012
FEV1≤ 70% of FVC NR 4 trials (n = 727)
HH 18 μg
RMT 1.25–10 μg
Safety: incidence of
cardiac arrhythmias
Tashkin D, et al.
Eur Respir J. 2014;44
Suppl 58:923 [35]
Safety analysis in patients with renal impairment included in
placebo-controlled trials of once-daily tiotropium Respimat®
5 μg (7 trials) or tiotropium HandiHaler® 18 μg (15 trials)
COPD and renal
impairment
NR n = 10,753 evaluable patients
Normal renal function,
mild and moderate renal
impairment
(respectively):
HH 18 μg (n = 860),
(n = 1099), (n = 448)
HH placebo (n = 700),
(n = 815), (n = 347)
RMT 5 μg (n = 1104),
(n = 1479), (n = 662)
RMT placebo (n = 1040),
(n = 1539), (n = 660)
Safety: AEs
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Table 1 Primary tiotropium trials and pooled, combined and database analyses included in this review. Publications were limited to those reporting tiotropium Respimat® and
tiotropium HandiHaler® data at the licensed doses (Continued)
Verhamme K, et al.
Eur Respir J. 2013; 42
Suppl 57:4632 [38]
Verhamme KM, et al.
Eur Respir J. 2013;42: 606–
15 [39]
Study of Integrated Primary Care Information Database
(large Dutch primary care database)
COPD NR n = 11,287 (24,522
episodes of tiotropium
use)
Safety: comorbidity
Abbreviations: AE adverse event, AUC area under the curve, COPD chronic obstructive pulmonary disease, ECG electrocardiogram, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HH SPIRIVA®
HandiHaler®, HRQoL health-related quality of life, MACE major adverse cardiovascular events, NCT National Clinical Trials database, NR not reported, RMT SPIRIVA®, Respimat®, SaO2 direct measurement of the oxygen
content of the blood, SGRQ St George’s Respiratory Questionnaire, TIOSPIR® TIOtropium Safety and Performance In Respimat®
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Fig. 3 Forest plot of adjusted mean difference in SGRQ total score between tiotropium Respimat® or tiotropium HandiHaler® and placebo: results
of a post-hoc pooled analysis [34]. CI, confidence interval; EXACTT, Exercise Endurance and COPD Treated With Tiotropium; MCID, minimal
clinically important difference; SAFE, SPIRIVA® Assessment of FEV1; TIPHON, Tiotropium: Influence sur la Perception de l’amélioration des activités
Habituelles Objectivée par une échelle Numérique; UPLIFT®, Understanding Potential Long-term Impacts on Function with Tiotropium
Fig. 2 Geometric mean tiotropium plasma concentration–time profile following multiple inhalations using tiotropium Respimat® or tiotropium
HandiHaler® [31]. (Adapted with permission from [31])
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and sleep quality in 200 patients with COPD, 6 months
after the start of treatment [25, 44]. At the end of
treatment (n = 188), both treatment groups showed
significant improvements in minimum SaO2 (p <0.001)
and percentage of sleep spent below 90% of SaO2
(TST90) (tiotropium Respimat®, p <0.001; tiotropium
HandiHaler®, p = 0.002) compared with baseline
(Respimat® vs. HandiHaler® for SaO2 and TST90 at
6 months: p = 0.83 and p = 0.04, respectively). Patients
treated with tiotropium Respimat® had significantly
better TST90 than did the patients treated with
tiotropium HandiHaler®. Sleep disturbance was highly
variable, but the durations of sleep stages (and therefore
overall sleep quality) were significantly improved in
the tiotropium Respimat® group compared with the
tiotropium HandiHaler® group (p ≤0.01).
Safety of tiotropium Respimat® compared with tiotropium
HandiHaler®
In the Respimat® dose-finding trials [26, 31, 33, 37], tio-
tropium treatment was well tolerated compared with
placebo, irrespective of the inhaler used, and similarly
low numbers of patients using tiotropium Respimat®
5 μg and tiotropium HandiHaler® 18 μg reported adverse
events.
Pooled and combined analyses of safety
A pre-specified pooled analysis of two 30-week cross-
over trials reported the following findings [37]: the
most common adverse events were COPD exacerba-
tions (9.6% with tiotropium Respimat® 5 μg, 11.2%
with tiotropium HandiHaler® 18 μg and 13% with pla-
cebo) and nasopharyngitis (7.5% with tiotropium
Respimat® 5 μg, 5.9% with tiotropium HandiHaler®
18 μg and 8.2% with placebo) [37]. COPD exacerbation,
dry mouth and nasopharyngitis were also the most
common adverse events in the study in Japanese patients,
and the number of adverse events reported in patients
receiving tiotropium Respimat® 5 μg and tiotropium
HandiHaler® 18 μg was similar (45 [30.6%] and 41 [27.9%],
respectively) [33].
A post-hoc, pooled, mixed-treatment analysis was
performed of all placebo-controlled or head-to-head
trials of tiotropium Respimat® 5 μg and tiotropium
HandiHaler® 18 μg with vital status follow-up (analysed
for death, n = 23,493), and those with duration of at least
1 year (analysed for exacerbations, n = 22,599) [28].
Tiotropium Respimat® 5 μg and tiotropium HandiHaler®
18 μg showed similar positive effects on mortality (odds
ratio 1.01; 95% confidence interval [CI] 0.89–1.15) and ex-
acerbations (odds ratio 0.90; 95% CI 0.81–1.01).
Prolongation of survival was not statistically significant
compared with placebo (odds ratios 0.92; 95% CI 0.77–
1.10 for tiotropium Respimat® 5 μg and 0.91; 95% CI
0.80–1.04 for tiotropium HandiHaler® 18 μg). Risk of
exacerbation was significantly lower for both tiotropium
Respimat® 5 μg and tiotropium HandiHaler® 18 μg com-
pared with placebo (odds ratios 0.79; 95% CI 0.70–0.88
and 0.87; 95% CI 0.78–0.98, respectively).
The safety of tiotropium delivered by Respimat® and
HandiHaler® was recently reviewed in a pooled analysis
of adverse event data from 28 HandiHaler® and seven
Respimat® studies involving 12,929 patients treated with
tiotropium and 11,626 patients treated with placebo
[30]. Patients were eligible for inclusion in these studies
if they had a diagnosis of COPD with FEV1 ≤ 70% of
FVC, were aged ≥40 years and had ≥10 pack-years of
smoking history. Patients were excluded if they had
significant disease other than COPD. Other exclusion
criteria in earlier studies were heart failure leading to
hospitalization in the previous 3 years, cardiac
arrhythmia requiring drug treatment or myocardial
infarction (MI) within the past year. More recent trials
only excluded life-threatening cardiac arrhythmia or
arrhythmia that needed a change in medication or heart
failure resulting in hospitalization in the past year, and/
or MI within the previous 6 months. These relatively
broad inclusion and exclusion criteria mean that the
patient population included in the analysis reflected
real-world heterogeneity of populations and phenotypes
of COPD patients, as far as is possible in randomized
clinical trials. The risk of adverse events (rate ratio 0.90;
95% CI 0.87–0.93) and serious adverse events (rate ratio
(0.94; 95% CI 0.89–0.99) was significantly lower in the
tiotropium group than in the placebo group, and the risk
of fatal adverse events (rate ratio 0.90; 95% CI 0.79–
1.01) and cardiac adverse events (rate ratio 0.93; 95% CI
0.85–1.02) was numerically lower in the tiotropium
group. Similar results were obtained when tiotropium
HandiHaler® 18 μg and tiotropium Respimat® 5 μg
groups were analysed separately, and no increased risk
of cardiac, vascular, and respiratory, thoracic and medi-
astinal disorders, or stroke, were observed in the tiotro-
pium groups, except for a higher risk of ischaemic heart
disease for tiotropium versus placebo in the tiotropium
Respimat® 5 μg group (rate ratio 1.6 [95% CI 1.04–2.49])
but not in the tiotropium HandiHaler® 18 μg group.
However, the incidence rates were lower in the pla-
cebo Respimat® group than in the placebo HandiHaler®
group (1.25 vs. 1.89), and there was no evidence of
increased risk of major adverse cardiovascular events
(MACE) or fatal MACE in the tiotropium group compared
with placebo, or in tiotropium HandiHaler® 18 μg and tio-
tropium Respimat® 5 μg groups separately. These results do
not indicate an increased overall risk for fatal or cardiovas-
cular events in COPD patients during tiotropium treatment,
and support the findings from the TIOSPIR® (Tiotropium
Safety and Performance in Respimat) trial—the largest
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randomized, double-blind, parallel-group study of patients
with COPD, which did not show any relevant differences
between tiotropium HandiHaler® 18 μg and tiotropium
Respimat® 5 μg [48]. The findings of TIOSPIR® with regard
to the safety of tiotropium HandiHaler® 18 μg and tiotro-
pium Respimat® 5 μg are discussed in more detail later in
this review.
The issue of whether inhaled anticholinergics and, in
particular, tiotropium administered by Respimat®, may
induce cardiac arrhythmias in a vulnerable subpopula-
tion with cardiovascular morbidity has been discussed in
the literature [39, 46, 49]. In this context, the results of a
combined analysis of all tiotropium (HandiHaler® 18 μg
and/or Respimat® 1.25–10 μg) trials in COPD involving
Holter electrocardiogram (ECG) monitoring, and con-
ducted between 2003 and 2012 [32], are important. In the
four trials that were included in the analysis, patients were
required to have a diagnosis of COPD with FEV1 ≤ 70%
of FVC, were aged ≥40 years and had ≥10 pack-years of
smoking history. Holter ECGs were evaluated for heart
rate, pauses (absence of a heart beat for more than 3 sec-
onds), supraventricular premature beats and ventricular
premature beats. Maintenance therapy with either tiotro-
pium Respimat® 5 μg or tiotropium HandiHaler® 18 μg
was not associated with changes in any of these variables
(Table 2). The authors commented that the results are in
line with those of TIOSPIR®, which found no evidence
that tiotropium Respimat® is associated with an increased
risk of mortality, especially in patients with cardiac dis-
ease, or specifically arrhythmias at baseline.
An analysis of safety in patients with renal impairment
(n = 10,753 evaluable patients) included in placebo-
controlled trials of once-daily tiotropium Respimat® 5 μg
(seven trials) or tiotropium HandiHaler® 18 μg (15 trials)
has been conducted [35]. The incidence of adverse
events, serious adverse events or fatal adverse events
with either tiotropium Respimat® 5 μg or tiotropium
HandiHaler® 18 μg showed no association with mild to
moderately impaired renal function (Fig. 4). Results for
severe renal impairment were limited due to the low
number of patients (n = 52).
Database analysis of mortality
A report from a Dutch primary care database (source
population 11,287, including 24,522 episodes of tiotropium
use) found that the use of tiotropium Respimat® was
associated with an almost 30% increase of mortality
compared with tiotropium HandiHaler® [38, 39]. The asso-
ciation was strongest for cardiovascular/cerebrovascular
death. These findings, however, are not supported by
those of the large prospective TIOSPIR® trial, which
showed no difference in mortality between patients using
tiotropium Respimat® or tiotropium HandiHaler®, as
described below.
The TIOSPIR® study
The TIOSPIR® study was a 2–3 year, randomized, double-
blind, parallel-group trial enrolling 17,135 patients with
COPD [43, 48]. The aim of the trial was to evaluate
the safety and efficacy of once-daily tiotropium Respimat®
2.5 or 5 μg and tiotropium HandiHaler® 18 μg in a large
COPD population. Patients were permitted to continue
their usual respiratory therapy (with the exception of other
inhaled anticholinergics). Patients with cardiovascular
diseases were allowed to participate, except for patients
with heart failure resulting in hospitalization or cardiac
arrhythmia requiring new drug treatment during the
previous year, or experiencing MI within the past
6 months.
The primary safety endpoint for TIOSPIR® was time
to all-cause mortality and the primary efficacy end-
point was time to first COPD exacerbation; secondary
outcome measures included the number of exacerba-
tions and time to the first MACE. For the primary
endpoint of all-cause mortality, tiotropium Respimat®
5 μg was non-inferior to tiotropium HandiHaler®
18 μg (hazard ratio 0.96; 95% CI 0.84−1.09). Analysis
of causes of death as assigned by TIOSPIR® investiga-
tors compared with those assigned by a mortality
adjudication committee (MAC) found that fewer
deaths were assigned by the MAC to cardiac disor-
ders in the tiotropium HandiHaler® 18 μg group than
in the tiotropium Respimat® 5 μg group, although this
was not a significant effect (the CI of the rate ratio
was overlapping 1) [42].
TIOSPIR® showed no significant difference between
tiotropium Respimat® 5 μg and tiotropium HandiHaler®
18 μg for the primary efficacy endpoint of risk of
first exacerbation (hazard ratio [HR] 0.98; 95% CI
0.93−1.03; p = 0.42). The proportions of patients with
exacerbations (47.9% vs. 48.9%) and rates of exacer-
bations per patient-year (0.59; 95% CI 0.56−0.61 and
0.59; 95% CI 0.57−0.61) were similar between the
tiotropium Respimat® 5 μg and tiotropium HandiHaler®
18 μg groups (Fig. 5).
Safety profiles of tiotropium Respimat® 5 μg and
tiotropium HandiHaler® 18 μg were similar in the TIOSPIR®
population. The incidence of MACE (3.9% vs. 3.6%) and
causes of death (including death from cardiovascular
causes, incidence 2.0% vs. 1.8%) were comparable for the
tiotropium Respimat® 5 μg and tiotropium HandiHaler®
18 μg groups [48].
The spirometry sub-study of TIOSPIR® (n = 1370)
found that tiotropium Respimat® 5 μg was non-
inferior to tiotropium HandiHaler® 18 μg for adjusted
mean trough FEV1 (averaged over 24–120 weeks:
difference vs. HandiHaler® −10 mL; 95% CI −38−18)
[23, 24, 48]. Adjusted mean trough FVC was also
similar between treatment groups.
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Table 2 Summary of cardiac safety (Holter ECG) data for patients receiving tiotropium Respimat® or tiotropium HandiHaler® in four
randomized trials. Placebo data are shown for comparison [32]
Respimat® 5 μg HandiHaler® 18 μg Placebo
Average heart rate (BPM), mean ± SD (min–max)
Study 205.284
Baseline – 79.89 ± 10.88 (59–108) 81.35 ± 9.14 (52–97)
Day 84 – 80.19 ± 9.78 (61–103) 81.12 ± 12.36 (54–140)
Studies 205.254/255
Baseline 77.64 ± 10.05 (50–100) – 79.26 ± 11.56 (55–136)
Day 281 77.23 ± 9.68 (56–99) – 77.62 ± 11.21 (53–111)
Study 205.458
Day 26 75.36 ± 10.77 (51–108) 75.83 ± 10.35 (58–100) 75.91 ± 10.91 (56–106)
Day 29 76.87 ± 10.82 (54–104) 77.39 ± 10.44 (55–104) 77.02 ± 10.36 (59–103)
Pauses, n/N (%)
Study 205.284
Baseline – 2/74 (2.7) 1/65 (1.5)
Day 84 – 3/86 (3.5) 0
Studies 205.254/255
Baseline 2/121 (1.7) – 3/109 (2.8)
Day 281 1/103 (1.0) – 2/73 (2.7)
Study 205.458
Day 26 0 1/113 (0.9) 0
Day 29 0 0 0
VPB singles, n/N (%)
Study 205.284
Baseline – 61/74 (82.4) 54/65 (83.1)
Day 84 – 71/86 (82.6) 58/78 (74.4)
Studies 205.254/255
Baseline 112/121 (92.6) – 95/109 (87.2)
Day 281 86/103 (83.5) – 66/73 (90.4)
Study 205.458
Day 26 90/112 (80.4) 88/113 (77.9) 93/117 (79.5)
Day 29 94/116 (81.0) 96/114 (84.2) 91/116 (78.4)
SVPB singles, n/N (%)
Study 205.284
Baseline – 66/74 (89.2) 60/65 (92.3)
Day 84 – 82/86 (95.3) 74/78 (94.9)
Studies 205.254/255
Baseline 113/121 (93.4) – 101/109 (92.7)
Day 281 96/103 (93.2) – 68/73 (93.2)
Study 205.458
Day 26 100/112 (89.3) 105/113 (92.9) 111/117 (94.9)
Day 29 108/116 (93.1) 107/114 (93.9) 109/116 (94.0)
BPM beats per minute, ECG electrocardiogram, FAS full analysis set, N number of patients with non-missing data; n, number of patients with event, SD standard de-
viation, SVPB supraventricular premature beat, VPB ventricular premature beat. A pause was defined as absence of a heart beat for >3 s
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Fig. 4 Forest plot of incidence rate ratios (95% CI) of on-treatment AEs by renal function at baseline: post-hoc analysis of tiotropium trials [35]. Renal
function classification using National Institute for Health and Clinical Excellence (NICE) criteria: normal ≥90 mL/min, mild ≥60 to <90 mL/min, moderate
≥30 to <60 mL/min, severe <30 mL/min creatinine. Incidence rate ratios could not be calculated for severe renal impairment due to low patient
numbers. Where there were no events in the placebo or tiotropium group, incidence rate ratios could not be calculated (division by zero) or are equal
to zero, respectively, and are not graphically displayed. AE, adverse event; CI, confidence interval; FAE, fatal adverse event; IRR, incidence rate ratio; SAE,
serious adverse event; SOC, System Organ Class (Medical Dictionary for Regulatory Activities)
Fig. 5 a Kaplan–Meier plot for COPD exacerbation in the TIOSPIR® trial. b Corresponding hazard ratio (95% confidence interval) for COPD
exacerbation. (Adapted with permission from [48]). CI, confidence interval; COPD, chronic obstructive pulmonary disease
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Post-hoc subgroup analyses including data from the
TIOSPIR® study have further supported the clinical
equivalence of tiotropium Respimat® 5 μg and tiotro-
pium HandiHaler® 18 μg. Analyses of the 4-year
placebo-controlled Understanding Potential Long-term
Impacts on Function with Tiotropium (UPLIFT®) trial of
tiotropium HandiHaler® and TIOSPIR® found that in pa-
tients who had experienced a cardiac event (for which
they would have been excluded at baseline) during the
trials, the risk of serious (including fatal) cardiac or
MACE was not increased by tiotropium (tiotropium
HandiHaler® 18 μg or tiotropium Respimat® 5 μg) [36].
Similar findings were obtained in a separate analysis of
patients experiencing cardiac events during TIOSPIR®
(Fig. 6) [41].
An analysis of data from patients from TIOSPIR®
who were naïve to anticholinergic treatment at baseline
(n = 6966) found that, as in the primary analysis [48], these
patients had similar safety and exacerbation efficacy
profiles when treated with tiotropium Respimat® 5 μg or
tiotropium HandiHaler® 18 μg [40]. The HR was 0.93
(95% CI 0.75−1.17) for risk of death (measured as time to
death) and 0.99 (95% CI 0.90−1.08) for exacerbations
(measured as time to first exacerbation).
An analysis of patients treated with tiotropium Handi-
Haler® 18 μg at TIOSPIR® baseline, and who were ran-
domized and subsequently received tiotropium Respimat®
5 μg during the study, showed that they had similar risks
for all-cause mortality (HR 0.79; 95% CI 0.58–1.07), fatal
MACE (HR 0.67; 95% CI 0.33–1.34), MACE (HR 0.69;
95% 0.44–1.08) and exacerbations (HR 0.96; 95% CI 0.86
−1.08) as patients who continued to be treated with tiotro-
pium HandiHaler® 18 μg [27, 29].
Discussion
This systematic review evaluated pharmacokinetic, effi-
cacy and safety results from published studies of tiotro-
pium Respimat® and tiotropium HandiHaler® at the
licensed doses (5 and 18 μg), respectively, with the aim
of summarizing evidence that might inform the choice
of tiotropium inhaler in clinical practice.
The results of several randomized dose-finding studies
and the TIOSPIR® study have demonstrated that tiotro-
pium Respimat® 5 μg has a pharmacokinetic, efficacy and
safety profile that is comparable with that of tiotropium
HandiHaler® 18 μg [24, 26, 31, 33, 37, 48]. Results from
post-hoc and pooled analyses provide further confirmation
that overall lung function, exacerbation, quality of life and
safety outcomes are equivalent for the two tiotropium in-
halers across a range of patient subtypes. The efficacy and
safety of tiotropium, when administered by either Respi-
mat® or HandiHaler®, is supported by previously published
systematic reviews [7, 22, 49, 50].
There has been debate about the safety of inhaled anti-
cholinergics and, in particular, the cardiac safety of tio-
tropium administered by Respimat®, which was triggered
by meta-analysis [46] and database analysis [39] that re-
ported an increase in mortality in patients treated with
tiotropium Respimat®. The meta-analysis examined data
from five randomized, controlled trials of tiotropium
Respimat® [46] and found an increased risk of mortality
compared with placebo. However, there was no direct
Fig 6 Post-hoc analysis of fatal, serious and cardiac AEs in patients receiving tiotropium Respimat® 5 μg and tiotropium HandiHaler® 18 μg and
experiencing recent serious cardiac events during TIOSPIR® [41]. Events were counted from the day following the initial cardiac event through
drug stop +30 days. FAEs, fatal adverse events; MACE, major adverse cardiovascular events; NS, not significant; SAEs, serious adverse events;
TIOSPIR®, Tiotropium Safety and Performance in Respimat®
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comparison with tiotropium HandiHaler®, and the ana-
lysis was limited by differences in the populations stud-
ied, the tiotropium dose used, and length of follow-up.
The investigators also noted that low event rates pre-
cluded precise estimates of risk [46]. The authors of the
Dutch database analysis commented that it was unclear
whether the apparent association between the use of tio-
tropium Respimat® and an increased risk of death was
causal or due to residual confounding by COPD severity
[39]. One source of confounding could be the substantial
differences in the population treated with tiotropium
HandiHaler® and tiotropium Respimat®. Although the
analysis was adjusted for several factors, the adjustment
was incomplete, and a channelling effect towards more
severe patients being treated with tiotropium Respimat®
was described by the same group [51].
The tiotropium safety data from the meta- and database
analyses are in contrast to the results of TIOSPIR® [48], in-
cluding ~17,000 patients, which provided the most robust
data available to date regarding the comparative safety
and efficacy of the two tiotropium formulations, and par-
ticularly the licensed doses. Key findings of TIOSPIR®
were that tiotropium Respimat® 5 μg was non-inferior to
tiotropium HandiHaler® 18 μg in terms of all-cause mor-
tality and that the risk of cardiovascular mortality or
MACE did not differ significantly between the two treat-
ment groups [41, 43]. In addition, there was no increased
risk of subsequent cardiac events with tiotropium Handi-
Haler® 18 μg or tiotropium Respimat® 5 μg in patients ex-
periencing a serious cardiac event during the trial (the risk
of MACE was actually lower with tiotropium HandiHaler®
18 μg than with placebo in UPLIFT®) [36]. This is an im-
portant finding, as many patients with COPD in clinical
practice are likely to have underlying cardiac disease, yet
such patients are typically excluded from randomized clin-
ical trials of maintenance COPD treatments. The TIOS-
PIR® trial did not exclude most patients in routine care
with cardiac diseases including stable coronary artery
disease or stable arrhythmias, making it a study that was
inclusive of the majority of patients that are typically seen
in clinical practice. It is acknowledged that the data from
TIOSPIR® are more robust than those arising from the
meta-analyses or database studies [7, 52], which had previ-
ously raised concerns about an increased mortality risk
with the tiotropium Respimat® inhaler [38, 39, 46].
Limitations of this review are the descriptive presenta-
tion of the findings (not subject to statistical analysis)
and the inclusion of secondary and post-hoc analyses
(such as those conducted on sub-populations of patients
in the TIOSPIR® trial). Generally, it is challenging to
draw firm conclusions from the results obtained across
numerous trials, owing to differences in study duration
and design. However, the studies assessed here included
COPD patients across a broad range of disease severity
(from moderate to very severe), and the TIOSPIR® trial
allowed patients to receive tiotropium HandiHaler® or
tiotropium Respimat® while continuing with their usual
COPD maintenance therapy (thus helping to reflect clin-
ical practice) [43, 48]. Overall, the review encompasses a
large body of data on tiotropium HandiHaler® or tiotro-
pium Respimat® from randomized trials, pooled analyses
and database studies.
The studies reviewed here suggest that clinical efficacy
appears equivalent between tiotropium Respimat® 5 μg
and tiotropium HandiHaler® 18 μg, and as such, patient
preferences and acceptance of different inhaler types be-
come more important in the prescribing decision [53, 54].
Patient preference for an inhaler is an important deter-
minant of treatment adherence, which is a key consider-
ation for treatment choices in chronic diseases [1, 55, 56].
In addition, mishandling of inhalers is a common issue
that may result in reduced symptom control [57], and
therefore for any individual patient, it is important to
assess ability to use the different types of available device.
The inhalation and handling characteristics of tiotropium
Respimat® have been assessed by patients with COPD, and
was preferred to alternative inhalers, including metered-
dose inhalers and dry powder inhalers [56, 58–60].
For physicians who may be considering whether patients
are suitable candidates to switch from tiotropium Handi-
Haler® to tiotropium Respimat®, TIOSPIR® data show that
in patients who switched from tiotropium HandiHaler® to
tiotropium Respimat®, mortality, cardiac safety and exacer-
bation outcomes were similar to those who remained on
tiotropium HandiHaler® [27, 29]. From the patient’s per-
spective, studies have suggested that they find it easy to
switch from tiotropium HandiHaler® to tiotropium Respi-
mat®, and have reported high levels of preference for, and
adherence to, tiotropium Respimat® [61–65].
It also appears from “real-world” experience that phy-
sicians are already confident to prescribe tiotropium
Respimat® for their patients with more severe disease
and/or comorbidities. A study of the Dutch Integrated
Primary Care Information Database was performed to
compare patient characteristics at the time of the first
prescription of tiotropium Respimat® or tiotropium
HandiHaler® (source population 501,474, including
11,753 tiotropium users) [51]. COPD was found to be
more severe and underlying comorbidities were more
prevalent for first-time users of tiotropium Respimat®
compared with tiotropium HandiHaler®. Also, in Italy, a
drug utilization study conducted in patients receiving
tiotropium during 2011–2012 found that users of tiotro-
pium Respimat® and tiotropium HandiHaler® (n = 4390)
had similar characteristics [66], but in this study, the
probability of switching to tiotropium Respimat® was
greater in patients with severe respiratory disease. If tio-
tropium Respimat® is being selected for patients with
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more severe COPD in clinical practice, this might help
to explain the increased mortality risk suggested by earl-
ier database and meta-analyses. However, TIOSPIR®
demonstrated that tiotropium Respimat® has a similar
safety and exacerbation efficacy profile to tiotropium
HandiHaler® in patients with moderate-to-very severe
COPD [48], supporting its use across the disease
spectrum.
Conclusions
The approval of tiotropium Respimat® in many countries
has provided physicians with a choice of inhaler for the
delivery of tiotropium maintenance therapy for their pa-
tients with COPD. Published evidence from comparative
studies suggests that tiotropium Respimat® 5 μg and tio-
tropium HandiHaler® 18 μg provide similar clinical out-
comes in COPD, indicating that physicians can choose
between the two inhalers with confidence. Factors other
than efficacy and safety, such as patient preference for a
particular inhaler, ease of use and handling, and the effi-
ciency of drug delivery (which has improved significantly
for tiotropium with the Respimat® device) [20] should
also be taken into account with the aim of optimizing
adherence and clinical outcomes with long-term tiotro-
pium maintenance therapy.
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